Acute cellular rejection predominated by monocytes is a severe form of rejection in human renal recipients with or without Campath-1H (alemtuzumab) induction therapy.

Division of Laboratory Medicine, Geisinger Medical Center, Danville, PA, USA.
American Journal of Transplantation (Impact Factor: 6.19). 04/2005; 5(3):604-7. DOI: 10.1111/j.1600-6143.2004.00712.x
Source: PubMed

ABSTRACT Campath-1H has been used successfully for induction and has resulted in a low rate of acute cellular rejection (ACR) in renal transplantation in combination with various postoperative immunosuppression regimens. This study was undertaken to investigate the extent of monocyte involvement in ACR, with or without Campath-1H induction. We found that monocytes represented the majority of inflammatory cells in grades Ib or higher ACR, but not with Ia type of ACR, regardless of the status of Campath-1H induction. Cases of ACR, following Campath-1H induction, appear to demonstrate a 'pure form' of monocytic ACR, whereas monocytes were mixed with many other types of inflammatory cells in the cases of ACR in the absence of Campath-1H induction. In addition with Campath-1H induction, the cases of monocyte-predominant ACR were found to uniformly exhibit a good response to corticosteroid treatment. We conclude that monocyte-predominate ACR may represent a severe form of rejection, with or without Campath-1H treatment.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of review: Much attention has recently been placed on transplanting anti-Human Leukocyte Antigen (HLA) sensitized patients and using ABO-incompatible organs. To achieve this goal, the antibodies must be removed. It is therefore timely to provide a review that updates the current literature on drugs and modalities being used including intravenous immunoglobulin-G, mycophenolate mofetil, sirolimus, Campath, Protein A immunoabsorption, and rituximab. Recent findings: The most important recent study, a randomized trial of intravenous immunoglobulin-G versus placebo, confirmed the efficacy of intravenous immunoglobulin-G for desensitization. Campath appears to be unable to prevent antibody-mediated rejection and therefore is probably not suitable for desensitization. Animal data suggest that immunoabsorption columns might be working through the systemic exposure of Protein A. Rituximab, a B-cell specific antibody, appears to be safe and to have some efficacy as a sole agent in elimination of alloantibodies but most likely will require combination therapy. Newer agents such as humanized anti-CD20 and drugs targeting other B-cell antigens such as BAFF (B-cell Activation Factor of the TNF Family) and APRIL (A PRoliferation-Inducing Ligand) are being developed. Summary: Although many reports are appearing that demonstrate successful transplants, there is a major deficiency in controlled clinical trials with these drugs. Focus over the near future should be to prove the efficacy through the use of randomized trials.
    Current Opinion in Organ Transplantation 11/2005; 10(4):279-283. · 2.38 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Mixed rejection in kidney transplantation consists of histologic and/or serological evidence of both cellular and humoral components. As it is not confined to a distinct category in the Banff classification, how to best manage these patients is not clear. The aim of this study was to determine the incidence and outcome of morphological T-cell-mediated rejection (TCMR) with a humoral component, defined as the presence of either DSA or C4d, compared with the outcome of pure TCMR. We retrospectively studied 922 consecutive renal transplant recipients and analyzed patients with TCMR according to the evidence of a humoral component. A total of 147 cases of morphological TCMR were analyzed. Of these, 92 (62.6%) had "pure" TCMR and 55 (37.4%) had "mixed" TCMR on the index biopsy. On univariant analysis, diffuse C4d (odds ratio [OR]=10.9, 95% confidence interval [CI]=1.8-66.9, P=0.01) and DSA positivity at the time of index biopsy (OR=2.8, 95% CI=1.2-6.6, P=0.02) were associated with allograft loss, whereas arteritis (OR=0.5, 95% CI=0.2-1.2, P=0.11) and glomerulitis (OR=0.9, 95% CI=0.4-2.1, P=0.8) were not. Arteritis was associated with subsequent antibody-mediated rejection (OR=4.9, 95% CI=1.1-20.8, P=0.03), and glomerulitis was associated with the development of transplant glomerulopathy (OR=10.7, 95% CI=3.1-37.1, P<0.01). On the multivariate analysis, only patients with C4d and DSA were at risk of graft failure (OR=4.9, 95% CI=2.0-12.0, P<0.01) in the medium term. TCMR with a humoral component has a worse prognosis when compared with pure TCMR. As such, it is important to test for alloantibody in cases of morphological TCMR to optimize patient management. Such cases might benefit from more aggressive immunotherapy.
    Transplantation 01/2014; · 3.78 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT:   Here we report a case of granulomatous tubulointerstitial nephritis occurring seven d after kidney transplantation. The development of macroscopic hematuria, acute prostatitis, a mild elevation of serum creatinine, and high-grade fever together with a urine culture positive for adenovirus antigen suggested adenovirus infection. Episode biopsy seven d after kidney transplantation showed granulomatous tubulointerstitial nephritis evidenced by predominantly CD68-positive cell infiltration and epithelioid cells at focal tubulointerstitial spaces with severe tubulitis, such as destruction of the tubular basement membrane. After intervention consisting of a reduction of the immunosuppressive therapy and administration of intravenous immunoglobulin (IVIG) and ganciclovir, renal function returned to normal, with a rapid recovery of the pathological as well as clinical features within a month. In renal allografts, adenovirus infection should be considered during the early phase following transplantation, even within seven d, especially when granulomatous tubulointerstitial nephritis is present.
    Clinical Transplantation 06/2007; 21(s18):23 - 26. · 1.49 Impact Factor

Full-text (2 Sources)

Available from
Sep 11, 2014